{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T04:24:11Z","timestamp":1790915051156,"version":"4.1.0"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,11,28]],"date-time":"2019-11-28T00:00:00Z","timestamp":1574899200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,11,28]],"date-time":"2019-11-28T00:00:00Z","timestamp":1574899200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Alz Res Therapy"],"published-print":{"date-parts":[[2019,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Results from recent clinical studies suggest that cerebrospinal fluid (CSF) biomarkers that are indicative of Alzheimer\u2019s disease (AD) can be replicated in blood, e.g. amyloid-beta peptides (A\u03b2<jats:sub>42<\/jats:sub> and A\u03b2<jats:sub>40<\/jats:sub>) and neurofilament light chain (NFL). Such data proposes that blood is a rich source of potential biomarkers reflecting central nervous system pathophysiology and should be fully explored for biomarkers that show promise in CSF. Recently, soluble fragments of the triggering receptor expressed on myeloid cells 2 (sTREM2) protein in CSF have been reported to be increased in prodromal AD and also in individuals with <jats:italic>TREM2<\/jats:italic> rare genetic variants that increase the likelihood of developing dementia.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>In this study, we measured the levels of plasma sTREM2 and plasma NFL using the MesoScale Discovery and single molecule array platforms, respectively, in 48 confirmed <jats:italic>TREM2<\/jats:italic> rare variant carriers and 49 non-carriers.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Our results indicate that there are no changes in plasma sTREM2 and NFL concentrations between <jats:italic>TREM2<\/jats:italic> rare variant carriers and non-carriers. Furthermore, plasma sTREM2 is not different between healthy controls, mild cognitive impairment (MCI) or AD.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Concentrations of plasma sTREM2 do not mimic the recent changes found in CSF sTREM2.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13195-019-0545-5","type":"journal-article","created":{"date-parts":[[2019,11,28]],"date-time":"2019-11-28T23:02:39Z","timestamp":1574982159000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":41,"title":["Plasma levels of soluble TREM2 and neurofilament light chain in TREM2 rare variant carriers"],"prefix":"10.1186","volume":"11","author":[{"given":"Nicholas J.","family":"Ashton","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Su\u00e1rez-Calvet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda","family":"Heslegrave","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdul","family":"Hye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Razquin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pau","family":"Pastor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raquel","family":"Sanchez-Valle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 L.","family":"Molinuevo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pieter Jelle","family":"Visser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaj","family":"Blennow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela K.","family":"Hodges","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrik","family":"Zetterberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,11,28]]},"reference":[{"issue":"11","key":"545_CR1","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1038\/s41582-018-0079-7","volume":"14","author":"H Hampel","year":"2018","unstructured":"Hampel H, O'Bryant SE, Molinuevo JL, Zetterberg H, Masters CL, Lista S, et al. Blood-based biomarkers for Alzheimer disease: mapping the road to the clinic. Nat Rev Neurol. 2018;14(11):639\u201352.","journal-title":"Nat Rev Neurol"},{"issue":"7691","key":"545_CR2","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1038\/nature25456","volume":"554","author":"A Nakamura","year":"2018","unstructured":"Nakamura A, Kaneko N, Villemagne VL, Kato T, Doecke J, Dore V, et al. High performance plasma amyloid-beta biomarkers for Alzheimer\u2019s disease. Nature. 2018;554(7691):249\u201354.","journal-title":"Nature."},{"key":"545_CR3","doi-asserted-by":"publisher","first-page":"26801","DOI":"10.1038\/srep26801","volume":"6","author":"S Janelidze","year":"2016","unstructured":"Janelidze S, Stomrud E, Palmqvist S, Zetterberg H, van Westen D, Jeromin A, et al. Plasma beta-amyloid in Alzheimer\u2019s disease and vascular disease. Sci Rep. 2016;6:26801.","journal-title":"Sci Rep"},{"issue":"8","key":"545_CR4","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1016\/j.jalz.2017.06.2266","volume":"13","author":"V Ovod","year":"2017","unstructured":"Ovod V, Ramsey KN, Mawuenyega KG, Bollinger JG, Hicks T, Schneider T, et al. Amyloid beta concentrations and stable isotope labeling kinetics of human plasma specific to central nervous system amyloidosis. Alzheimers Dement. 2017;13(8):841\u20139.","journal-title":"Alzheimers Dement"},{"issue":"5","key":"545_CR5","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1001\/jamaneurol.2016.6117","volume":"74","author":"Niklas Mattsson","year":"2017","unstructured":"Mattsson N, Andreasson U, Zetterberg H, Blennow K, Alzheimer\u2019s Disease Neuroimaging I. Association of plasma neurofilament light with neurodegeneration in patients with Alzheimer disease. JAMA Neurol. 2017;74(5):557\u2013566.","journal-title":"JAMA Neurology"},{"issue":"1","key":"545_CR6","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/s13195-018-0404-9","volume":"10","author":"P Lewczuk","year":"2018","unstructured":"Lewczuk P, Ermann N, Andreasson U, Schultheis C, Podhorna J, Spitzer P, et al. Plasma neurofilament light as a potential biomarker of neurodegeneration in Alzheimer\u2019s disease. Alzheimers Res Ther. 2018;10(1):71.","journal-title":"Alzheimers Res Ther"},{"issue":"1","key":"545_CR7","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s40478-018-0649-3","volume":"7","author":"NJ Ashton","year":"2019","unstructured":"Ashton NJ, Leuzy A, Lim YM, Troakes C, Hortobagyi T, Hoglund K, et al. Increased plasma neurofilament light chain concentration correlates with severity of post-mortem neurofibrillary tangle pathology and neurodegeneration. Acta Neuropathol Commun. 2019;7(1):5.","journal-title":"Acta Neuropathol Commun"},{"issue":"7","key":"545_CR8","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1016\/S1474-4422(16)00070-3","volume":"15","author":"B Olsson","year":"2016","unstructured":"Olsson B, Lautner R, Andreasson U, Ohrfelt A, Portelius E, Bjerke M, et al. CSF and blood biomarkers for the diagnosis of Alzheimer\u2019s disease: a systematic review and meta-analysis. Lancet Neurol. 2016;15(7):673\u201384.","journal-title":"Lancet Neurol"},{"issue":"8","key":"545_CR9","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1136\/jnnp-2018-320106","volume":"90","author":"Lorenzo Gaetani","year":"2019","unstructured":"Gaetani L, Blennow K, Calabresi P, Di Filippo M, Parnetti L, Zetterberg H. Neurofilament light chain as a biomarker in neurological disorders. J Neurol Neurosurg Psychiatry. 2019;90(8):870-81.","journal-title":"Journal of Neurology, Neurosurgery & Psychiatry"},{"issue":"10","key":"545_CR10","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1212\/WNL.0000000000003680","volume":"88","author":"O Hansson","year":"2017","unstructured":"Hansson O, Janelidze S, Hall S, Magdalinou N, Lees AJ, Andreasson U, et al. Blood-based NfL: a biomarker for differential diagnosis of parkinsonian disorder. Neurology. 2017;88(10):930\u20137.","journal-title":"Neurology."},{"issue":"13","key":"545_CR11","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1212\/WNL.0000000000003154","volume":"87","author":"JD Rohrer","year":"2016","unstructured":"Rohrer JD, Woollacott IO, Dick KM, Brotherhood E, Gordon E, Fellows A, et al. Serum neurofilament light chain protein is a measure of disease intensity in frontotemporal dementia. Neurology. 2016;87(13):1329\u201336.","journal-title":"Neurology."},{"issue":"8","key":"545_CR12","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1016\/S1474-4422(17)30124-2","volume":"16","author":"LM Byrne","year":"2017","unstructured":"Byrne LM, Rodrigues FB, Blennow K, Durr A, Leavitt BR, Roos RAC, et al. Neurofilament light protein in blood as a potential biomarker of neurodegeneration in Huntington's disease: a retrospective cohort analysis. Lancet Neurol. 2017;16(8):601\u20139.","journal-title":"Lancet Neurol"},{"issue":"17","key":"545_CR13","doi-asserted-by":"publisher","first-page":"1827","DOI":"10.1212\/WNL.0000000000003246","volume":"87","author":"N Mattsson","year":"2016","unstructured":"Mattsson N, Zetterberg H, Janelidze S, Insel PS, Andreasson U, Stomrud E, et al. Plasma tau in Alzheimer disease. Neurology. 2016;87(17):1827\u201335.","journal-title":"Neurology."},{"issue":"8","key":"545_CR14","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1016\/j.jalz.2018.02.013","volume":"14","author":"MM Mielke","year":"2018","unstructured":"Mielke MM, Hagen CE, Xu J, Chai X, Vemuri P, Lowe VJ, et al. Plasma phospho-tau181 increases with Alzheimer\u2019s disease clinical severity and is associated with tau- and amyloid-positron emission tomography. Alzheimers Dement. 2018;14(8):989\u201397.","journal-title":"Alzheimers Dement"},{"issue":"2","key":"545_CR15","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1007\/s00401-008-0389-8","volume":"116","author":"P Foulds","year":"2008","unstructured":"Foulds P, McAuley E, Gibbons L, Davidson Y, Pickering-Brown SM, Neary D, et al. TDP-43 protein in plasma may index TDP-43 brain pathology in Alzheimer\u2019s disease and frontotemporal lobar degeneration. Acta Neuropathol. 2008;116(2):141\u20136.","journal-title":"Acta Neuropathol"},{"issue":"2","key":"545_CR16","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1159\/000112832","volume":"5","author":"R Barbour","year":"2008","unstructured":"Barbour R, Kling K, Anderson JP, Banducci K, Cole T, Diep L, et al. Red blood cells are the major source of alpha-synuclein in blood. Neurodegener Dis. 2008;5(2):55\u20139.","journal-title":"Neurodegener Dis"},{"issue":"1","key":"545_CR17","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s13195-015-0124-3","volume":"7","author":"H Kvartsberg","year":"2015","unstructured":"Kvartsberg H, Portelius E, Andreasson U, Brinkmalm G, Hellwig K, Lelental N, et al. Characterization of the postsynaptic protein neurogranin in paired cerebrospinal fluid and plasma samples from Alzheimer\u2019s disease patients and healthy controls. Alzheimers Res Ther. 2015;7(1):40.","journal-title":"Alzheimers Res Ther"},{"issue":"2","key":"545_CR18","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1056\/NEJMoa1211851","volume":"368","author":"R Guerreiro","year":"2013","unstructured":"Guerreiro R, Wojtas A, Bras J, Carrasquillo M, Rogaeva E, Majounie E, et al. TREM2 variants in Alzheimer\u2019s disease. N Engl J Med. 2013;368(2):117\u201327.","journal-title":"N Engl J Med"},{"issue":"2","key":"545_CR19","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1056\/NEJMoa1211103","volume":"368","author":"T Jonsson","year":"2013","unstructured":"Jonsson T, Stefansson H, Steinberg S, Jonsdottir I, Jonsson PV, Snaedal J, et al. Variant of TREM2 associated with the risk of Alzheimer\u2019s disease. N Engl J Med. 2013;368(2):107\u201316.","journal-title":"N Engl J Med"},{"issue":"3","key":"545_CR20","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1016\/j.neurobiolaging.2013.09.009","volume":"35","author":"E Cuyvers","year":"2014","unstructured":"Cuyvers E, Bettens K, Philtjens S, Van Langenhove T, Gijselinck I, van der Zee J, et al. Investigating the role of rare heterozygous TREM2 variants in Alzheimer\u2019s disease and frontotemporal dementia. Neurobiol Aging. 2014;35(3):726 e11\u20139.","journal-title":"Neurobiol Aging"},{"issue":"4","key":"545_CR21","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1016\/j.neurobiolaging.2013.09.017","volume":"35","author":"B Borroni","year":"2014","unstructured":"Borroni B, Ferrari F, Galimberti D, Nacmias B, Barone C, Bagnoli S, et al. Heterozygous TREM2 mutations in frontotemporal dementia. Neurobiol Aging. 2014;35(4):934 e7\u201310.","journal-title":"Neurobiol Aging"},{"key":"545_CR22","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/1750-1326-8-19","volume":"8","author":"S Rayaprolu","year":"2013","unstructured":"Rayaprolu S, Mullen B, Baker M, Lynch T, Finger E, Seeley WW, et al. TREM2 in neurodegeneration: evidence for association of the p.R47H variant with frontotemporal dementia and Parkinson\u2019s disease. Mol Neurodegener. 2013;8:19.","journal-title":"Mol Neurodegener"},{"issue":"4","key":"545_CR23","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1001\/jamaneurol.2013.6237","volume":"71","author":"J Cady","year":"2014","unstructured":"Cady J, Koval ED, Benitez BA, Zaidman C, Jockel-Balsarotti J, Allred P, et al. TREM2 variant p.R47H as a risk factor for sporadic amyotrophic lateral sclerosis. JAMA Neurol. 2014;71(4):449\u201353.","journal-title":"JAMA Neurol"},{"issue":"46","key":"545_CR24","doi-asserted-by":"publisher","first-page":"33027","DOI":"10.1074\/jbc.M113.517540","volume":"288","author":"P Wunderlich","year":"2013","unstructured":"Wunderlich P, Glebov K, Kemmerling N, Tien NT, Neumann H, Walter J. Sequential proteolytic processing of the triggering receptor expressed on myeloid cells-2 (TREM2) protein by ectodomain shedding and gamma-secretase-dependent intramembranous cleavage. J Biol Chem. 2013;288(46):33027\u201336.","journal-title":"J Biol Chem"},{"key":"545_CR25","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.neulet.2017.09.034","volume":"660","author":"D Feuerbach","year":"2017","unstructured":"Feuerbach D, Schindler P, Barske C, Joller S, Beng-Louka E, Worringer KA, et al. ADAM17 is the main sheddase for the generation of human triggering receptor expressed in myeloid cells (hTREM2) ectodomain and cleaves TREM2 after Histidine 157. Neurosci Lett. 2017;660:109\u201314.","journal-title":"Neurosci Lett"},{"issue":"10","key":"545_CR26","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.15252\/emmm.201707672","volume":"9","author":"K Schlepckow","year":"2017","unstructured":"Schlepckow K, Kleinberger G, Fukumori A, Feederle R, Lichtenthaler SF, Steiner H, et al. An Alzheimer-associated TREM2 variant occurs at the ADAM cleavage site and affects shedding and phagocytic function. EMBO Mol Med. 2017;9(10):1356\u201365.","journal-title":"EMBO Mol Med."},{"issue":"10","key":"545_CR27","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.15252\/emmm.201707673","volume":"9","author":"P Thornton","year":"2017","unstructured":"Thornton P, Sevalle J, Deery MJ, Fraser G, Zhou Y, Stahl S, et al. TREM2 shedding by cleavage at the H157-S158 bond is accelerated for the Alzheimer\u2019s disease-associated H157Y variant. EMBO Mol Med. 2017;9(10):1366\u201378.","journal-title":"EMBO Mol Med"},{"issue":"Pt 11","key":"545_CR28","doi-asserted-by":"publisher","first-page":"3081","DOI":"10.1093\/brain\/awn217","volume":"131","author":"L Piccio","year":"2008","unstructured":"Piccio L, Buonsanti C, Cella M, Tassi I, Schmidt RE, Fenoglio C, et al. Identification of soluble TREM-2 in the cerebrospinal fluid and its association with multiple sclerosis and CNS inflammation. Brain. 2008;131(Pt 11):3081\u201391.","journal-title":"Brain."},{"issue":"243","key":"545_CR29","doi-asserted-by":"publisher","first-page":"243ra86","DOI":"10.1126\/scitranslmed.3009093","volume":"6","author":"G Kleinberger","year":"2014","unstructured":"Kleinberger G, Yamanishi Y, Suarez-Calvet M, Czirr E, Lohmann E, Cuyvers E, et al. TREM2 mutations implicated in neurodegeneration impair cell surface transport and phagocytosis. Sci Transl Med. 2014;6(243):243ra86.","journal-title":"Sci Transl Med"},{"issue":"5","key":"545_CR30","doi-asserted-by":"publisher","first-page":"466","DOI":"10.15252\/emmm.201506123","volume":"8","author":"M Suarez-Calvet","year":"2016","unstructured":"Suarez-Calvet M, Kleinberger G, Araque Caballero MA, Brendel M, Rominger A, Alcolea D, et al. sTREM2 cerebrospinal fluid levels are a potential biomarker for microglia activity in early-stage Alzheimer\u2019s disease and associate with neuronal injury markers. EMBO Mol Med. 2016;8(5):466\u201376.","journal-title":"EMBO Mol Med."},{"key":"545_CR31","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s13024-016-0071-x","volume":"11","author":"A Heslegrave","year":"2016","unstructured":"Heslegrave A, Heywood W, Paterson R, Magdalinou N, Svensson J, Johansson P, et al. Increased cerebrospinal fluid soluble TREM2 concentration in Alzheimer\u2019s disease. Mol Neurodegener. 2016;11:3.","journal-title":"Mol Neurodegener"},{"issue":"6","key":"545_CR32","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1007\/s00401-016-1533-5","volume":"131","author":"L Piccio","year":"2016","unstructured":"Piccio L, Deming Y, Del-Aguila JL, Ghezzi L, Holtzman DM, Fagan AM, et al. Cerebrospinal fluid soluble TREM2 is higher in Alzheimer disease and associated with mutation status. Acta Neuropathol. 2016;131(6):925\u201333.","journal-title":"Acta Neuropathol"},{"issue":"1","key":"545_CR33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13024-018-0301-5","volume":"14","author":"M Suarez-Calvet","year":"2019","unstructured":"Suarez-Calvet M, Morenas-Rodriguez E, Kleinberger G, Schlepckow K, Araque Caballero MA, Franzmeier N, et al. Early increase of CSF sTREM2 in Alzheimer\u2019s disease is associated with tau related-neurodegeneration but not with amyloid-beta pathology. Mol Neurodegener. 2019;14(1):1.","journal-title":"Mol Neurodegener"},{"key":"545_CR34","doi-asserted-by":"crossref","unstructured":"Rauchmann BS, Schneider-Axmann T, Alexopoulos P, Perneczky R, Alzheimer\u2019s Disease Neuroimaging I. CSF soluble TREM2 as a measure of immune response along the Alzheimer\u2019s disease continuum. Neurobiol Aging 2019;74:182\u2013190.","DOI":"10.1016\/j.neurobiolaging.2018.10.022"},{"issue":"369","key":"545_CR35","doi-asserted-by":"publisher","first-page":"369ra178","DOI":"10.1126\/scitranslmed.aag1767","volume":"8","author":"M Suarez-Calvet","year":"2016","unstructured":"Suarez-Calvet M, Araque Caballero MA, Kleinberger G, Bateman RJ, Fagan AM, Morris JC, et al. Early changes in CSF sTREM2 in dominantly inherited Alzheimer\u2019s disease occur after amyloid deposition and neuronal injury. Sci Transl Med. 2016;8(369):369ra178.","journal-title":"Sci Transl Med"},{"key":"545_CR36","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1111\/j.1749-6632.2009.05064.x","volume":"1180","author":"S Lovestone","year":"2009","unstructured":"Lovestone S, Francis P, Kloszewska I, Mecocci P, Simmons A, Soininen H, et al. AddNeuroMed--the European collaboration for the discovery of novel biomarkers for Alzheimer\u2019s disease. Ann N Y Acad Sci. 2009;1180:36\u201346.","journal-title":"Ann N Y Acad Sci"},{"issue":"6","key":"545_CR37","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1016\/j.jalz.2014.05.1749","volume":"10","author":"A Hye","year":"2014","unstructured":"Hye A, Riddoch-Contreras J, Baird AL, Ashton NJ, Bazenet C, Leung R, et al. Plasma proteins predict conversion to dementia from prodromal disease. Alzheimers Dement. 2014;10(6):799\u2013807 e2.","journal-title":"Alzheimers Dement"},{"issue":"Pt 11","key":"545_CR38","doi-asserted-by":"publisher","first-page":"3042","DOI":"10.1093\/brain\/awl279","volume":"129","author":"A Hye","year":"2006","unstructured":"Hye A, Lynham S, Thambisetty M, Causevic M, Campbell J, Byers HL, et al. Proteome-based plasma biomarkers for Alzheimer\u2019s disease. Brain. 2006;129(Pt 11):3042\u201350.","journal-title":"Brain."},{"issue":"2","key":"545_CR39","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1016\/j.neurobiolaging.2013.08.011","volume":"35","author":"A Ruiz","year":"2014","unstructured":"Ruiz A, Dols-Icardo O, Bullido MJ, Pastor P, Rodriguez-Rodriguez E, Lopez de Munain A, et al. Assessing the role of the TREM2 p.R47H variant as a risk factor for Alzheimer\u2019s disease and frontotemporal dementia. Neurobiol Aging. 2014;35(2):444 e1\u20134.","journal-title":"Neurobiol Aging"},{"issue":"6","key":"545_CR40","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.1016\/j.neurobiolaging.2012.12.018","volume":"34","author":"BA Benitez","year":"2013","unstructured":"Benitez BA, Cooper B, Pastor P, Jin SC, Lorenzo E, Cervantes S, et al. TREM2 is associated with the risk of Alzheimer\u2019s disease in Spanish population. Neurobiol Aging. 2013;34(6):1711 e15\u20137.","journal-title":"Neurobiol Aging"},{"issue":"3","key":"545_CR41","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.3233\/JAD-170564","volume":"60","author":"BLR Reijs","year":"2017","unstructured":"Reijs BLR, Ramakers I, Elias-Sonnenschein L, Teunissen CE, Koel-Simmelink M, Tsolaki M, et al. Relation of odor identification with Alzheimer\u2019s disease markers in cerebrospinal fluid and cognition. J Alzheimers Dis. 2017;60(3):1025\u201334.","journal-title":"J Alzheimers Dis"},{"issue":"1","key":"545_CR42","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1002\/ana.25385","volume":"85","author":"T Ohara","year":"2019","unstructured":"Ohara T, Hata J, Tanaka M, Honda T, Yamakage H, Yoshida D, et al. Serum soluble triggering receptor expressed on myeloid cells 2 as a biomarker for incident dementia: the Hisayama study. Ann Neurol. 2019;85(1):47\u201358.","journal-title":"Ann Neurol"},{"issue":"8","key":"545_CR43","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1084\/jem.194.8.1111","volume":"194","author":"A Bouchon","year":"2001","unstructured":"Bouchon A, Hernandez-Munain C, Cella M, Colonna M. A DAP12-mediated pathway regulates expression of CC chemokine receptor 7 and maturation of human dendritic cells. J Exp Med. 2001;194(8):1111\u201322.","journal-title":"J Exp Med"},{"issue":"6","key":"545_CR44","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1046\/j.1471-4159.2002.01243.x","volume":"83","author":"CD Schmid","year":"2002","unstructured":"Schmid CD, Sautkulis LN, Danielson PE, Cooper J, Hasel KW, Hilbush BS, et al. Heterogeneous expression of the triggering receptor expressed on myeloid cells-2 on adult murine microglia. J Neurochem. 2002;83(6):1309\u201320.","journal-title":"J Neurochem"},{"issue":"4","key":"545_CR45","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1084\/jem.20030027","volume":"198","author":"J Paloneva","year":"2003","unstructured":"Paloneva J, Mandelin J, Kiialainen A, Bohling T, Prudlo J, Hakola P, et al. DAP12\/TREM2 deficiency results in impaired osteoclast differentiation and osteoporotic features. J Exp Med. 2003;198(4):669\u201375.","journal-title":"J Exp Med"},{"issue":"2","key":"545_CR46","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/j.nbd.2004.09.007","volume":"18","author":"A Kiialainen","year":"2005","unstructured":"Kiialainen A, Hovanes K, Paloneva J, Kopra O, Peltonen L. Dap12 and Trem2, molecules involved in innate immunity and neurodegeneration, are co-expressed in the CNS. Neurobiol Dis. 2005;18(2):314\u201322.","journal-title":"Neurobiol Dis"},{"issue":"3","key":"545_CR47","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1086\/342259","volume":"71","author":"J Paloneva","year":"2002","unstructured":"Paloneva J, Manninen T, Christman G, Hovanes K, Mandelin J, Adolfsson R, et al. Mutations in two genes encoding different subunits of a receptor signaling complex result in an identical disease phenotype. Am J Hum Genet. 2002;71(3):656\u201362.","journal-title":"Am J Hum Genet"},{"issue":"12","key":"545_CR48","doi-asserted-by":"publisher","first-page":"2890","DOI":"10.1016\/j.neurobiolaging.2013.06.005","volume":"34","author":"R Guerreiro","year":"2013","unstructured":"Guerreiro R, Bilgic B, Guven G, Bras J, Rohrer J, Lohmann E, et al. Novel compound heterozygous mutation in TREM2 found in a Turkish frontotemporal dementia-like family. Neurobiol Aging. 2013;34(12):2890 e1\u20135.","journal-title":"Neurobiol Aging"},{"issue":"13","key":"545_CR49","doi-asserted-by":"publisher","first-page":"1837","DOI":"10.15252\/embj.201796516","volume":"36","author":"G Kleinberger","year":"2017","unstructured":"Kleinberger G, Brendel M, Mracsko E, Wefers B, Groeneweg L, Xiang X, et al. The FTD-like syndrome causing TREM2 T66M mutation impairs microglia function, brain perfusion, and glucose metabolism. EMBO J. 2017;36(13):1837\u201353.","journal-title":"EMBO J"},{"issue":"5","key":"545_CR50","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1111\/tra.12264","volume":"16","author":"JS Park","year":"2015","unstructured":"Park JS, Ji IJ, An HJ, Kang MJ, Kang SW, Kim DH, et al. Disease-associated mutations of TREM2 alter the processing of N-linked oligosaccharides in the golgi apparatus. Traffic. 2015;16(5):510\u20138.","journal-title":"Traffic."},{"key":"545_CR51","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.neurobiolaging.2016.02.029","volume":"42","author":"T Jiang","year":"2016","unstructured":"Jiang T, Tan L, Chen Q, Tan MS, Zhou JS, Zhu XC, et al. A rare coding variant in TREM2 increases risk for Alzheimer\u2019s disease in Han Chinese. Neurobiol Aging. 2016;42:217 e1\u20133.","journal-title":"Neurobiol Aging"},{"key":"545_CR52","doi-asserted-by":"crossref","unstructured":"Kober DL, Alexander-Brett JM, Karch CM, Cruchaga C, Colonna M, Holtzman MJ, et al. Neurodegenerative disease mutations in TREM2 reveal a functional surface and distinct loss-of-function mechanisms. Elife. 2016;5:e20391.","DOI":"10.7554\/eLife.20391"},{"issue":"4","key":"545_CR53","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1016\/j.jalz.2016.07.004","volume":"13","author":"W Song","year":"2017","unstructured":"Song W, Hooli B, Mullin K, Jin SC, Cella M, Ulland TK, et al. Alzheimer\u2019s disease-associated TREM2 variants exhibit either decreased or increased ligand-dependent activation. Alzheimers Dement. 2017;13(4):381\u20137.","journal-title":"Alzheimers Dement"},{"issue":"32","key":"545_CR54","doi-asserted-by":"publisher","first-page":"12634","DOI":"10.1074\/jbc.RA118.002352","volume":"293","author":"A Sudom","year":"2018","unstructured":"Sudom A, Talreja S, Danao J, Bragg E, Kegel R, Min X, et al. Molecular basis for the loss-of-function effects of the Alzheimer\u2019s disease-associated R47H variant of the immune receptor TREM2. J Biol Chem. 2018;293(32):12634\u201346.","journal-title":"J Biol Chem"},{"issue":"6","key":"545_CR55","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1016\/j.jalz.2014.05.1751","volume":"10","author":"CF Slattery","year":"2014","unstructured":"Slattery CF, Beck JA, Harper L, Adamson G, Abdi Z, Uphill J, et al. R47H TREM2 variant increases risk of typical early-onset Alzheimer\u2019s disease but not of prion or frontotemporal dementia. Alzheimers Dement. 2014;10(6):602\u20138 e4.","journal-title":"Alzheimers Dement"},{"issue":"12","key":"545_CR56","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1016\/j.jalz.2016.06.005","volume":"12","author":"JD Gispert","year":"2016","unstructured":"Gispert JD, Suarez-Calvet M, Monte GC, Tucholka A, Falcon C, Rojas S, et al. Cerebrospinal fluid sTREM2 levels are associated with gray matter volume increases and reduced diffusivity in early Alzheimer\u2019s disease. Alzheimers Dement. 2016;12(12):1259\u201372.","journal-title":"Alzheimers Dement"}],"container-title":["Alzheimer's Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-019-0545-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13195-019-0545-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-019-0545-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,27]],"date-time":"2020-11-27T00:30:24Z","timestamp":1606437024000},"score":1,"resource":{"primary":{"URL":"https:\/\/alzres.biomedcentral.com\/articles\/10.1186\/s13195-019-0545-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,28]]},"references-count":56,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["545"],"URL":"https:\/\/doi.org\/10.1186\/s13195-019-0545-5","relation":{},"ISSN":["1758-9193"],"issn-type":[{"value":"1758-9193","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11,28]]},"assertion":[{"value":"11 June 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 October 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 November 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"KB has served as a consultant or at advisory boards for Alector, Alzheon, CogRx, Biogen, Lilly, Novartis and Roche Diagnostics, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB, a GU Venture-based platform company at the University of Gothenburg, all unrelated to the work presented in this paper. HZ has served at scientific advisory boards for Roche Diagnostics, Wave, Samumed and CogRx; has given lectures in symposia sponsored by Alzecure and Biogen; and is a co-founder of Brain Biomarker Solutions in Gothenburg AB, a GU Venture-based platform company at the University of Gothenburg. The other authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"94"}}